FMC amends credit agreement to allow $200M Corteva IP license refund lien

FMC CORP

Amendment No. 7 permits first-priority lien on Rimisoxafen IP to secure up to $200M refund obligation to Corteva Agriscience.
FMC receives $200M upfront from Corteva under a supply and license agreement; amount subject to contingent refund.
Existing credit agreement liens on Rimi IP are released; liens will be re-granted if Corteva lien terminates.
Required Lenders approved; conditions include no default, solvency certificate, and KYC documentation.
Subsidiary guarantors reaffirm guarantees and security interests excluding released Rimi IP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.